Aurobindo Pharma Limited (AUROPHARMA) Fair Value & Analysis

Healthcare · IN · Market cap ₹891B

A solid business, but screening 16% overvalued on our models.

What matters now

• Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
• Our model range runs from ₹1,005 (bear) to ₹1,675 (bull), base ₹1,340. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 66/100 (solid quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range ₹397.96 – ₹1,621 · fair‑value band ₹1,005 – ₹1,675 · the ₹1,589 price screens above the ₹1,340 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Aurobindo Pharma Limited (AUROPHARMA) currently trades at ₹1,589, while our model-based Fair Value estimate is ₹1,340, implying the stock looks roughly 15.7% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Aurobindo Pharma Limited generated revenue of ₹337B at a net margin of 10.4%. Revenue grew 5.6% year over year. It earns a return on equity of 9.9%. The balance sheet holds a net cash position of ₹18.0B. Fundamentals as of Jul 17, 2026

Our scenario range runs from ₹1,005 (bear case) to ₹1,675 (bull case); at ₹1,589, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 56% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -16%, AUROPHARMA screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (₹1,532) versus Dividend Discount (₹69.48). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables.

Full company description

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Aurobindo Pharma Limited reported revenue of ₹337B in FY2026 versus ₹235B in FY2022, a compound +9.4%/yr. Reported net income was ₹35.0B in FY2026, compounding +7.3%/yr from FY2022.

AUROPHARMA screens 16% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.